Lupus and Aging: Relief for Older Patients
Lupus Patients Show Unexpected reversal of Age-Related Inflammation
A UCSF Study Reveals a Surprising Pattern in Inflammaging, Offering New Insights into Autoimmune Disease
San francisco, CA – In a captivating twist on our understanding of aging and disease, researchers at the University of California, San Francisco (UCSF) have discovered that individuals with lupus exhibit a unique pattern of inflammation that appears to reverse with age, a phenomenon they’ve termed “inflammaging.” While this reversal isn’t complete, it offers a compelling new perspective on how autoimmune diseases interact with the aging process.
The Puzzle of Inflammaging and Lupus
As we age, our bodies naturally experience a gradual increase in chronic, low-grade inflammation, a process known as inflammaging. This persistent inflammation is linked to a host of age-related diseases, from cardiovascular issues to neurodegenerative disorders. However, in people living with lupus, an autoimmune disease where the immune system mistakenly attacks healthy tissues, this age-related inflammatory trend seems to take an unexpected turn.
The UCSF team observed that certain genes and proteins associated with inflammaging were abnormally high in mid-life lupus patients. But as thes individuals entered their later decades, the expression of these inflammatory markers began to decrease, moving towards levels seen in healthy older adults.
A “Reversal” with a Caveat
“Inflammaging seemed to be reversed in the lupus patients,” explained Chaz Langelier, MD, PhD, associate professor of medicine at UCSF and senior author of the paper. “But it wasn’t fully reversed. the lupus patients still had a greater level of inflammatory signaling compared to healthy adults in older age.”
This partial reversal aligns with what dr. patterson, a clinician involved in the study, has observed in her own lupus patients – a return to a state that more closely resembles healthy aging. This suggests that the disease process itself might be influencing the body’s inflammatory trajectory in ways we haven’t fully understood until now.
Future Directions: Targeting Inflammation Across the Lifespan
The implications of these findings are critically important. Understanding this age-related inflammatory reversal in lupus could pave the way for more personalized and effective treatment strategies. The research team is already planning their next steps.
“Next, the team intends to test whether drugs that block interferons are more or less effective in lupus patients at different ages,” Dr. Langelier shared.Interferons are a type of signaling protein that plays a crucial role in the immune response, and their dysregulation is ofen implicated in autoimmune diseases like lupus. By examining how age affects the efficacy of interferon-blocking drugs, researchers hope to refine treatment protocols.
Beyond lupus, the UCSF team is eager to apply their approach to other inflammation-related conditions. They aim to extend their research to conditions such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and atherosclerosis, all of which involve significant inflammatory components. This broader application could unlock new therapeutic avenues for a wide range of chronic diseases.
The study, published in a leading scientific journal, highlights the complex interplay between autoimmune diseases and the aging process, offering a beacon of hope for improved patient care and a deeper understanding of human health.
Authors: Other UCSF authors contributing to this groundbreaking research include Rithwik Narendra, Hoang Van Phan, Ana Almonte-Loya, Emily C. Lydon, MD, Christina Love, Michiko Shimoda, PhD, Padmini Deosthale, MS, Lenka Maliskova, Walter Eckalbar, PhD, Gabriela K. Fragiadakis, PhD, Jinoos Yazdany, MD, MPH, Maria Dall’Era, MD, Patricia Katz, PhD, Chun Jimmie Ye, PhD, and Marina Sirota, PhD. A thorough list of authors can be found in the published paper.
Funding:* This vital work was made possible thru the generous support of the National Institutes of Health (R01 AR069616, K23AT011768, P30 AI027763), the US Centers for Disease Control and Prevention (CDC), and the Chan Zuckerberg Biohub.